EVE Health Group Limited (AU:EVE)
ASX:EVE
Want to see AU:EVE full AI Analyst Report?
EVE Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.04
Previous CloseN/A
Volume9.81K
Average Volume (3M)774.07K
Market Cap
AU$7.22M
Enterprise ValueAU$3.85M
Total Cash (Recent Filing)AU$929.66K
Total Debt (Recent Filing)AU$38.51K
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,326,600
10 Day Avg. Volume491,958
30 Day Avg. Volume774,070
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.22
Price to Sales (P/S)2.49
P/FCF Ratio-2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureA very low debt-to-equity ratio (0.03) signals a conservative capital structure that reduces default and refinancing risk. This preserves financial optionality over the medium term, allowing the company to weather revenue volatility and prioritize strategic investments without heavy interest burdens.
Improving Free Cash FlowReported improvement in free cash flow growth indicates the company is starting to generate more cash after investments. Sustained FCF expansion supports reinvestment, debt avoidance, or strategic initiatives, improving long-term resilience if operating cash flow conversion trends continue upward.
Stable Equity Base And Gross Margin GainsA stable equity ratio combined with improving gross margins suggests the business retains capital strength while beginning to extract better unit economics. If margin improvements persist, they can compound profitability and free cash generation without increasing leverage, supporting durable recovery.
Bears Say
Sharp Revenue DeclineMaterial negative revenue growth (reported at roughly -32%) reflects shrinking top-line scale. Sustained revenue declines reduce operating leverage, limit bargaining power with suppliers, and compress the addressable market opportunity, making margin recovery and cash generation harder over the medium term.
Persistent Negative ProfitabilityOngoing negative net profit margins and loss-making operations indicate structural profitability challenges. Without durable margin turnarounds, the company will struggle to retain earnings, invest in growth, or achieve sustainable returns on equity, increasing the risk of dilution or strategic repositioning.
Weak Operating Cash ConversionOperating cash flow remains negative and converts poorly from reported earnings, signaling that profits (if any) are not translating into usable cash. This strains liquidity, may necessitate external funding, and undermines the durability of any free cash flow improvements without operational fixes.
EVE Health Group Limited News
EVE FAQ
What was EVE Health Group Limited’s price range in the past 12 months?
EVE Health Group Limited lowest share price was AU$0.02 and its highest was AU$0.04 in the past 12 months.
What is EVE Health Group Limited’s market cap?
EVE Health Group Limited’s market cap is AU$7.22M.
When is EVE Health Group Limited’s upcoming earnings report date?
EVE Health Group Limited’s upcoming earnings report date is Sep 02, 2026 which is in 68 days.
How were EVE Health Group Limited’s earnings last quarter?
EVE Health Group Limited released its earnings results on Feb 27, 2026. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.
Is EVE Health Group Limited overvalued?
According to Wall Street analysts EVE Health Group Limited’s price is currently Overvalued.
Does EVE Health Group Limited pay dividends?
EVE Health Group Limited does not currently pay dividends.
What is EVE Health Group Limited’s EPS estimate?
EVE Health Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EVE Health Group Limited have?
EVE Health Group Limited has 352,326,600 shares outstanding.
What happened to EVE Health Group Limited’s price movement after its last earnings report?
EVE Health Group Limited reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of EVE Health Group Limited?
Currently, no hedge funds are holding shares in AU:EVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EVE Health Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AU:EVE Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$10.0K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-44.35%
Trailing 12-Months
Asset Growth
348.70%
Trailing 12-Months
Company Description
EVE Health Group Limited
Based in Subiaco, Australia, Eve Health Group Limited, originally incorporated in 2003 as EVE Investments Limited, is an international provider of health, wellness, and nutritional products. The company operates across Australia, New Zealand, the Asia Pacific region, and North America. Its activities include the production of organic tea tree oils, the distribution of botanical oils, and the supply of a wide array of other oils such as essential oils, hydrosols, extracts, carrier oils, and seed oils. Furthermore, Eve Health Group offers organic raw honey and raw honey probiotic concentrates, alongside contract manufacturing services. A key area of its focus is developing medical nutrition solutions for chronic and lifestyle ailments, exemplified by Gluco Smooth, a product designed to help manage type 2 diabetes by moderating post-meal blood sugar levels, as well as providing various dietary intervention programs.
Technical Analysis
―
Fiji Kava Limited
―
Holista Colltech Limited
―
Nutritional Growth Solutions Ltd.
―
Forbidden Foods Ltd
―
Options Prices
Currently, No data available
---